Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited has reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma .
http://www.andhranews.net/Intl/2012/Once-Week-Oral-Proteasome-Inhibitor-MLN9708-Based-9873.htm
http://www.andhranews.net/Intl/2012/Once-Week-Oral-Proteasome-Inhibitor-MLN9708-Based-9873.htm
No comments:
Post a Comment